Actively Recruiting
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Led by Tempus AI · Updated on 2026-03-04
900
Participants Needed
12
Research Sites
422 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later. A way to find these cells is by looking for tiny bits of cancer DNA that are shed into the blood. This is called circulating tumor DNA (ctDNA). A simple blood test, often called a liquid biopsy, can detect this ctDNA. This research aims to see if finding this cancer DNA in the blood can help predict if a patient's cancer will return. It also may help find out if the treatment is working. Ultimately, the results of this research may help doctors better manage breast cancer and develop new and improved tests and treatments.
CONDITIONS
Official Title
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to participate in the research and provide biospecimens
- Willing and able to provide informed consent
- Must be diagnosed with breast cancer
- For Cohort 1A: Known or suspected HR+, HER2- breast cancer treated with curative intent (Stage II to III) at high risk of recurrence
- For Cohort 1B: Known or suspected HER2+ breast cancer treated with curative intent (Stage II to III), including HR+ or HR-
- For Cohort 1C: Known or suspected triple negative breast cancer treated with curative intent (Stage I to III)
- For Cohort 2A: Known or suspected HR+, HER2- breast cancer treated with curative intent (Stage II to III) at high risk of recurrence, post-surgery with no clinical evidence of disease
- For Cohort 2B: Known or suspected HER2+ breast cancer treated with curative intent (Stage II to III), post-surgery with no clinical evidence of disease
- For Cohort 2C: Known or suspected triple negative breast cancer treated with curative intent (Stage I to III), post-surgery with no clinical evidence of disease
- For Cohort 3: Known HR+, HER2- breast cancer treated with curative intent (Stage II to III), no evidence of disease for 5 or more years after diagnosis and at high risk of recurrence
You will not qualify if you...
- Not willing or able to follow the study procedures
- Having an active secondary cancer
- Diagnosed with another cancer within 3 years of the breast cancer diagnosis (except ductal carcinoma in situ within 3 years)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Birmingham Hematology Associates
Birmingham, Alabama, United States, 35223
Actively Recruiting
2
PIH Health Whittier Hospital
Whittier, California, United States, 90602
Actively Recruiting
3
Southern Illinois Hospital Services
Carbondale, Illinois, United States, 62902
Actively Recruiting
4
Cancer Care Specialist of Illinois
O'Fallon, Illinois, United States, 62269
Actively Recruiting
5
Goshen Center for Cancer Care
Goshen, Indiana, United States, 46526
Actively Recruiting
6
Trinity Health
Ann Arbor, Michigan, United States, 48106
Actively Recruiting
7
Oncology Hematology Associates
Springfield, Missouri, United States, 65807
Actively Recruiting
8
Cancer Care Specialist of Reno
Reno, Nevada, United States, 89511
Actively Recruiting
9
Summit Medical Group
Florham Park, New Jersey, United States, 07932
Actively Recruiting
10
Nashville General
Nashville, Tennessee, United States, 37208
Actively Recruiting
11
Cancer Care Northwest
Spokane Valley, Washington, United States, 99216
Actively Recruiting
12
Gunderson Health
La Crosse, Wisconsin, United States, 54601
Actively Recruiting
Research Team
G
GEMINI Breast Clinical Study Manager
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here